Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has earned an average rating of “Moderate Buy” from the fourteen research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $13.80.
IOVA has been the topic of a number of research analyst reports. Citizens Jmp raised their target price on Iovance Biotherapeutics from $8.00 to $12.00 and gave the company a “market outperform” rating in a report on Friday, November 6th. Robert W. Baird raised their target price on shares of Iovance Biotherapeutics from $6.00 to $11.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Wells Fargo & Company boosted their target price on shares of Iovance Biotherapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 30th. Barclays upped their price target on shares of Iovance Biotherapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Tuesday, September 29th.
View Our Latest Research Report on Iovance Biotherapeutics
Iovance Biotherapeutics Stock Down 1.0%
Shares of Iovance Biotherapeutics stock opened at $8.09 on Friday. The stock has a market capitalization of $3.74 billion, a price-to-earnings ratio of -15.26 and a beta of 0.88. Iovance Biotherapeutics has a twelve month low of $2.08 and a twelve month high of $15.37. The company has a 50-day simple moving average of $11.38 and a two-hundred day simple moving average of $6.03.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. The business had revenue of $121.47 million for the quarter, compared to the consensus estimate of $115.98 million. Iovance Biotherapeutics had a negative return on equity of 29.71% and a negative net margin of 58.20%. The business’s quarterly revenue was up 64.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Iovance Biotherapeutics will post -0.41 earnings per share for the current fiscal year.
Institutional Trading of Iovance Biotherapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in IOVA. Compass Financial Management LLC bought a new position in Iovance Biotherapeutics in the 3rd quarter valued at approximately $37,000. Valley National Advisers Inc. bought a new stake in Iovance Biotherapeutics during the 3rd quarter worth approximately $38,000. Root Financial Partners LLC bought a new stake in Iovance Biotherapeutics during the 3rd quarter worth approximately $44,000. Provenance Wealth Advisors LLC acquired a new position in Iovance Biotherapeutics in the 3rd quarter valued at approximately $61,000. Finally, GK Wealth Management LLC acquired a new position in Iovance Biotherapeutics in the 3rd quarter valued at approximately $107,000. 77.03% of the stock is currently owned by institutional investors.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, which are expanded in a laboratory and returned to the patient. The company’s lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.
Further Reading
- Five stocks we like better than Iovance Biotherapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
